Human TGF beta 1 Single-Use ELISA RSG Standard (2nd Generation)

Also known as: Transforming Growth Factor beta 1

RUO: For Research Use Only. Not for use in diagnostic procedures.

SKU# 39-8343

Cat. No. Size
39-8343-65 4 pack
Please inquire about custom configurations or bulk packaging.

To enable ordering, please select your country. Cookies will need to be enabled to continue on our website. View our Privacy Policy.

Data for Human TGF beta 1 Single-Use ELISA RSG Standard (2nd Generation).

Description

Description: Transforming Growth Factor beta (TGF beta) is a pleiotropic cytokine which exists in five isoforms, known as TGF beta 1-5, with homologies of 70-80% and no homology to TGF alpha. TGF beta 1 is the most abundant isoform and is ubiquitously expressed, while other isoforms are expressed in a more restricted manner. TGF beta 1 is highly conserved, with 100% sequence homology between the human, simian, bovine, porcine, and chicken proteins and 99% homology between the human and murine proteins. It is highly expressed in platelets and also produced by macrophages, lymphocytes, endothelial cells, chondrocytes, and leukemic cells.

TGF beta 1 is synthesized as a long precursor polypeptide, which is cleaved to yield the mature protein and the Latency Associated Peptide (LAP). LAP and mature TGF beta 1 remain non-covalently associated through secretion, forming homodimers known as the Small Latent Complex (SLC). Secretion can be induced by steroids, retinoids, EGF, NGF, vitamin D3, and IL-1. The bioactivity of mature TGF beta 1 is dependent on its release from LAP by conformational changes and proteolytic processing. Its activities include inhibition of cell growth in epithelial cells, endothelial cells, fibroblasts, neurons, lymphoid cells, and other hematopoietic cell types. TGF beta 1 also inhibits the proliferation of T cells and NK cells, downregulates the activities of activated macrophages, and blocks the anti-tumor activity of IL-2 – bearing lymphokine-activated killer (LAK) cells. Recently, TGF beta 1 has been found to have a critical role in the development of regulatory T cells and act as a costimulatory factor for expression of Foxp3. Dendritic cells exposed to tumors have been reported to secrete TGF beta 1 and stimulate the differntiation of CD4+CD25+ Treg cells from peripheral CD4+CD25- progeny. TGF beta 1-induced regulatory T cells have been termed iTreg.

Details
Reactivity Human
Reported Applications ELISA, ELISA Recombinant Standard, Functional Assays, Cytokine Bioassays
Documentation
TDS Link Download TDS
Related Products
Cat. No. Name Excite Emit Application Reg.
88-8350 Human/Mouse TGF beta 1 ELISA Ready-SET-Go! (2nd Generation) ELISA RUO
References

References: Fantini MC, Becker C, Tubbe I, Nikolaev A, Lehr HA, Galle P, Neurath MF. TGF-beta – induced Foxp3+ regulatory T cells suppress Th1-mediated experimental colitis. Gut. 2006 May;55(5):671-80.

Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4572-7.

Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993;8(1):1-9.

Miyazono K, Heldin CH. Structure, function and possible clinical application of transforming growth factor-beta. J Dermatol. 1992 Nov;19(11):644-7